Trial Profile

A Phase I/IIMulticenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients With B-Cell Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orelabrutinib (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors InnoCare Pharma

Most Recent Events

08 Jun 2026 Planned End Date changed from 30 Jan 2025 to 30 Jun 2026.
08 Jun 2026 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2026.
25 Apr 2024 This study has been completed in Poland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com